CAC
BMRN icon

Cowen and Company’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cowen and Company’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-37,500
Closed -$94K – 666
2022
Q1 		$94K Buy
+37,500
New +$3.14M 0.01% 279
2021
Q3 		– Sell
-13,800
Closed -$38K – 608
2021
Q2 		$38K Sell
13,800
-1,200
-8% -$95.1K ﹤0.01% 430
2021
Q1 		$153K Sell
15,000
-9,200
-38% -$752K 0.01% 290
2020
Q4 		$33K Buy
24,200
+14,900
+160% +$1.18M ﹤0.01% 301
2020
Q3 		$40K Buy
+9,300
New +$941K 0.01% 312

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cowen and Company's BMRN Position: Q1 2024 in Review

Cowen and Company sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 22,865 shares — an estimated $2.2M sold.

Cowen and Company first reported a position in BMRN in Q3 2020 and held it in 6 quarters. The position peaked at $2.2M in Q4 2023. 561 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

  • Cowen and Company reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Cowen and Company sold 22,865 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $2.2M.
  • Cowen and Company first reported a position in BioMarin Pharmaceuticals in Q3 2020 and held it in 6 quarters.
  • Cowen and Company's BioMarin Pharmaceuticals position peaked at $2.2M in Q4 2023.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.